MedTrace Logo

A Study of MG-K10 in Subjects With Atopic Dermatitis

NCT05466877 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 163

Last updated 2024-02-23

No results posted yet for this study

Summary

This study evaluates the preliminary efficacy of MG-K10 in subjects with moderate to severe asthma, and provides a basis for the design and dosing regimen of phase III clinical trials.

Conditions

Interventions

DRUG

MG-K10

MG-K10 Humanized Monoclonal Antibody Injection

DRUG

Placebo

MG-K10 Humanized Monoclonal Antibody Injection

Sponsors & Collaborators

  • Shanghai Mabgeek Biotech.Co.Ltd

    lead OTHER_GOV

Principal Investigators

  • Jinhua Xu, Medical Ph.D · Huashan Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-31
Primary Completion
2023-09-22
Completion
2024-05-26

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05466877 on ClinicalTrials.gov